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Background:  Motor neurone disease (MND) is a rare progressive neurodegenerative 
disorder in which selective degeneration of the motor neurones of the brain and spinal cord 
occurs. Progressive weakness of limb, bulbar and respiratory muscles eventually results in 
death. Most descriptive and epidemiological studies of MND have been performed in the 
industrialized countries of Europe and North America. We know very little about the 
incidence or prevalence of MND in Africa in general and South Africa in particular. 
However, anecdotal evidence based on observations by clinicians in the neurology and 
geriatric medical clinics at Groote Schuur Hospital suggest that the condition is not 
uncommonly seen, even in younger patients.  Furthermore, many cases appear to originate 
from the West Coast area of the Western Cape. 
Aims:  The proposed study aimed at describing the demographic and clinical characteristics 
of MND seen at Groote Schuur Hospital between 2005 and 2010.  I hypothesized that disease 
duration, measured from age of onset of first symptoms to death, would be shorter in patients 
with bulbar-onset disease, in younger-onset disease, and in patients with higher CSF protein 
and blood creatine kinase levels at baseline.  Furthermore, age of onset of the disease would 
be younger in familial compared with sporadic MND. I also hypothesized that smoking and 
certain occupational exposures might be risk factors for MND, that there would be a male 
preponderance of the disease, and that a disproportionate number of cases would come from 
the West Coast region. 
Methods:  This was a retrospective study. I reviewed the clinical notes of cases of motor 
neurone disease and collected data relevant to the aims and hypotheses described above. I 
applied the El Escorial diagnostic criteria for MND to check the validity of the diagnoses. 
Mortality data were obtained through the Burden of Diseases Research Unit at the South 
African Medical Research Council. 
Results:  Forty eight patients were identified who met El Escorial criteria for the diagnosis of 
probable or definite MND. The median age of onset of the disease was 54 (IQR 47-63) and 
the mean duration of the disease from earliest symptoms to death was 2 years (IQR 1-3).  
These did not differ significantly between bulbar and limb-onset disease sub-types. There 
was a male preponderance of the disease (60%) and the majority of patients (60%) were 
smokers. African patients tended to have a younger age of onset. Occupations involving 
potential exposure to chemicals were disproportionately represented in the MND patients 
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compared with the general population of the Western Cape. People from the West Coast 
region were not disproportionately represented in the patient population. Baseline CSF 
protein and serum creatine kinase levels were not associated with disease duration. 
Conclusion: The characteristics of MND cases seen at Groote Schuur Hospital between 2005 
and 2010 are similar to those described in the world literature. Smoking and chemical 
exposure may be risk factors for the disease. There was no evidence of clustering of cases. 
This study will serve as the basis for future larger prospective studies on MND prevalence 
and aetiology in South Africa. 
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Chapter 1: Introduction 
 
Motor neurone disease is a group of neurodegenerative disorders associated with selective 
degeneration of motor neurones in the brain and spinal cord. Jean-Martin Charcot first 
characterized the disease in 1869; it was then referred to as maladie de Charcot. The 
commonest form of motor neurone disease involves a combination of signs of upper and 
lower motor neurone degeneration. In the American literature the term amyotrophic lateral 
sclerosis or ALS is often used to describe this form of the disease. In the UK, the umbrella 
term motor neurone disease (MND) is more commonly used to describe all variants of the 
disease.   
Studies of the incidence, prevalence and demographic characteristics of patients with MND 
have mostly been done in the industrialized countries. We know very little about the disease 
in Africa in general and southern Africa in particular. Our anecdotal evidence from the 
neurology and geriatric medicine clinics suggests that the disease is not uncommonly seen in 
younger patients.     
This study aimed to describe the demographic and clinical characteristics of cases of MND 
seen at GSH between 2005 and 2010. I wished to determine whether a number of 
characteristics of MND, derived from studies in the developed world, are also seen locally. I 
also wished to test a number of hypotheses based on our clinical observations of the cases of 










Chapter 2: Rationale, motivation, background to the study and a 
review of the literature  
 
2.1 Introduction and history 
 
Jean–Marie Charcot, a French neurologist, used the term “amyotrophic lateral sclerosis” for 
the first time in 1874 (Charcot, 1874). It was also known as “maladie de Charcot” in France. 
Studies conducted between 1865 and 1869 by Charcot and his colleague Joffroy described 
the clinico-pathological features of the disease (Charcot, 1869).  In 1824 Charles Bell 
reported the motor functions of the anterior spinal nerve roots and the sensory functions of 
the posterior roots (Kazi, 2004). Aran in 1850 described cases of progressive muscular 
atrophy (PMA) (Aran, 1850). Five years later Cruveilhier correlated PMA with atrophy of the 
anterior horns of the spinal cord (Cruveilhier, 1853). In 1883 Dejerine related the disease of 
progressive bulbar palsy (PBP) to MND. In 1884 Kahler grouped the diseases of PMA, ALS 
and PBP together as “primary degenerations of the motor system” (Leigh, 1995). At this 
stage there were questions as to whether these syndromes, characterised by limb weakness, 
muscle atrophy and spasticity, were primarily muscle lesions or spinal cord diseases. Charcot 
was the first to establish the relationships between clinical presentations and autopsy 
findings. He used the disorder of motor neurone disease as the prototypic example of the use 
of his research method “méthode anatomoclinique” to correlate clinical signs detected in life 










Figure 1 Jean Marie Charcot, (source: Kumar, 2011) 
The term motor neurone disease (MND) was first used by Brain in 1933 (Turner, 2010). In 
the United States it is better known as amyotrophic lateral sclerosis (ALS) or Lou Gehrig 
disease, after the New York Yankees baseball player, Lou Gehrig, (Figure 2) who developed 












Figure 3 Joost Van Der Westhuizen, a South African rugby player, was diagnosed with MND 
in 2011 (source: Peacock, 2013) 
 
However, practically, MND and ALS are used interchangeably to describe the spectrum of 
motor neurone disorders.  
Throughout this text I shall use the term MND rather than ALS. 
This chapter aims to provide the reader with a background understanding of motor neurone 
disease (MND) and its classification.  It covers the definition of the disease, diagnostic 
criteria, clinical features, risk factors for its development and current management of the 
condition. 
Most of this literature has been based on studies conducted in Europe and North America. 
Very little is known about MND in developing countries, in the African continent in general; 
and southern Africa in particular. The clinical forms of MND in developing countries may 










MND is a progressive and ultimately fatal neurodegenerative condition that causes upper and 
lower motor neurone loss at many levels in the nervous system.  
Upper motor neurones, by definition, are neurones that originate in the motor cortex of the 
brain and terminate within the brainstem (corticobulbar tracts) or spinal cord (corticospinal 
tracts). They form part of the pyramidal motor system. Lower motor neurones are nerve cells 
that originate in the anterior horn of grey matter of the spinal cord or the brainstem cranial 
nerve nuclei. They end at the neuro-muscular junction and innervate the somatic limb 
muscles as well as the muscles of the lower face, tongue and oro-phaynx (Figure 4). 
 
Figure 4 UMN and LMN (source: Rowland, 2001) 
Damage to upper motor neurones results in muscle weakness, spasticity, and increased deep 
tendon reflexes (see table 1). Lower motor neurone lesions causes muscle atrophy 
(amyotrophy), fasciculations, weakness, and reduced or absent tendon reflexes (Table 1 and 
Figure 5). 
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Figure 5   Muscle atrophy in the upper limbs (source: Berger, 2005) 
In MND, the bulbar muscles involved in speech, chewing and swallowing are affected, as 
well as the muscles of the limbs, neck and trunk. The latter involves the muscles of 
respiration.  
Table 1: Features of upper and lower motor neurone dysfunction 
LMN dysfunction UMN dysfunction 
symptoms and signs symptoms and signs 
flaccid paralysis-weakness spastic paralysis-weakness 
muscle atrophy hypertonia/spasticity 
fasciculations hyperreflexia 
cramps extensor plantar responses 





The term “amyotrophy” is derived from Greek. “A” means “no” or “negative”. “Myo” refers 
to muscle and “trophic” means “nourishment”. Hence “no muscle nourishment” or wasting 
away. “Lateral” refers to the area of the corticospinal tracts in the spinal cord; and “sclerosis” 
means scarring or hardening (Wikipedia, 2014). 
In summary: ALS or MND is a disease in which the upper and lower motor neurones of the 
nervous system degenerate. The cause of this process, as we shall see, remains unclear. 
 
2.3 Incidence and prevalence worldwide  
 
The reported worldwide incidence and prevalence rates of MND vary little (Chiò, 2013) Most 
cases of MND are sporadic. About 5 to 10 % of MND is familial, with a Mendelian pattern of 
inheritance. MND affects people worldwide, but the exact incidence of the disease is not 
known. The incidence of sporadic MND in the 1990s was reported to be 1.5 to 2.7 per 
100,000 population/year (average of 1.9 per 100.000/year) in Europe and North America, 
with a fairly uniform incidence across these countries. The prevalence ranges from 2.7 to 7.4 
per 100, 000 in western Countries (Wijesekera, 2009). Males are affected more than females, 
with a male to female (M: F) ratio of 1, 5:1. A review published in 2001 found that the 
mortality rates of MND in the 1990s ranged from 1.54 to 2.55 per 100.000/year in the US 
population (Shaw, 2005). 
The mean age of onset of sporadic MND varies between 55-65 years depending on the study, 
with a median age of onset of 64 years (Haverkamp, 1995). Only 5% of cases have an onset 
before the age of 30 years. Bulbar onset is commoner in women and in older age groups, with 
43% of patients over the age of 70 presenting with bulbar symptoms compared to 15% below 
the age of 30 (Beghi, 2007). 
The incidence and prevalence peaks in older people between the ages of 65 and 74 years 
(Chiò, 2013). It decreases rapidly after 80 years of age (Logroscino, 2008). The incidence of 
MND is said to be increasing, but this is probably the result of improved diagnosis, better 
awareness of the disease and an ageing population. Death occurs in most patients within two 
to five years of the diagnosis (Rowland, 2001).  
In familial MND (fMND), the mean age of onset is a decade earlier than in sporadic cases, 
around 47-52 years. It affects males and females equally, and has a shorter survival (Veltema, 
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1990).  The inheritance is usually autosomal dominant, although autosomal recessive and X-
linked modes of inheritance may be seen in some pedigrees. 
During World War II an unusual frequency of MND combined with Parkinsonism and 
dementia was noted in the Pacific Island of Guam and the Kii peninsula of Japan. The 
prevalence in Guam has been reported to be 50 to 100 times higher than the prevalence 
anywhere else. The cause of MND associated with Parkinsonism and dementia in Guam is 
unknown, but it has been postulated that there might have been environmental or dietary 
triggers. However, since the late 1980s, the incidence in Guam has fallen to that of other 
regions of the world. 
There are reports of conjugal and other non-consanguineous clusters of MND outside the 
Western Pacific, with rates much higher than would be expected by chance. Examples 
include people who work or live in close proximity, play in the same sport teams, have been 
war evacuees, share an environmental peculiarity such as high soil selenium, or a common 
exposure such as leather or textile workers (Roman, 1996 ). 
 
2.3.1 Incidence and prevalence in Africa  
 
We have no reliable epidemiological information about the incidence and prevalence of 
MND in Africa. To my knowledge, there have been few studies to date reported in the 
literature from the African Continent. Radakhrisnan et al. studied the epidemiology of MND 
in Libya (Radhakrishnan, 1986). Their found that of 32 patients diagnosed with MND, 17 had 
ALS, 4 had PMA and 2 had PBA. The male to female ratio was 2, 3:1. The average incidence 
was 0.89/100.000 population/per year. The median age was 57 years. The median duration of 
illness for 5 patients after the onset of the disease was 30 months. The median survival time 
for all MND cases combined was 42 months. In a study by Iman and Ogunniyi from Nigeria, 
they found 16 cases diagnosed with MND. The mean age of onset was 38,6 years, there was a  
male preponderance (15 males and 1 female), all subjects had ALS, and trauma was the most 
frequent risk factor identified (Imam, 2004 ). In 1971, a study by Osuntokun from Ibadan, 
Nigeria, found that the incidence of MND was 0.35 per thousand; the mean age was lower 
compared with a Caucasian population in Nigeria, and had a better prognosis (Osuntokun, 
1971). Another study by Tekle-Haimanot et al. in 1990 described the prevalence of MND in 
Ethiopia as 5 per 100,000 of the population, but this and the Nigerian study included juvenile 
spinal muscular atrophy in the diagnosis of MND (Tekle-Haimanot, 1990).  
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 Abdullah 1997, in Sudan found 28 patients with MND, 19 of whom had ALS, 7 had PBP 
and 2 patients had PMA. A family history of the disease was found in 4 patients and those 
presented mainly with bulbar symptoms. Sudanese patients had an earlier age of onset and a 
better prognosis of the disease than their Caucasian counterparts (Abdulla, 1997).   
 
2.4 Diagnostic Criteria of MND 
 
The diagnosis of MND is made clinically using: 
1. the revised El Escorial criteria (EEDC)  (Brooks, 2000 ). 
2.  clinical features of both upper and lower motor neurone degeneration.  
3.  electrophysiological examinations, neuro-imaging and clinical laboratory tests to 
exclude potential mimics and other treatable conditions. 
4. repetition of clinical and electrophysiological examinations to ascertain evidence of 
progression. 
5. neuropathological examinations where available. 
 
2.4.1. The El Escorial diagnostic criteria (EEDC) 
 
MND is a clinical diagnosis. Thus far there are no specific biological markers for a definitive 
diagnosis. Clinical electrophysiology is the main supportive diagnostic aid when MND is 
suspected. The electrophysiological tests can demonstrate subclinical MND changes, in 
muscles considered not affected clinically (De Carvalho, 2005). It was Lambert and Mulder 
in 1957 who first suggested that electrophysiology could assist in the diagnosis of MND and 
in the exclusion of mimics of the disease. In 1969 they published a set of electrophysiological 
criteria for MND diagnosis (Lambert, 1969). The World Federation of Neurology (WFN) 
sub-committee on motor neurone disease convened a workshop in EL Escorial, Spain, in 
1990, to discuss and develop international clinical and electrophysiological criteria to 
diagnose MND (Brooks, 2000). These El Escorial diagnostic criteria (EEDC) criteria were 
revised in 1998 at Airlie House, Virginia (Brooks, 2000). The revised El Escorial criteria 
(EEDC) are summarized in table 2. The EEDC define four body regions to be evaluated: the 
(1) bulbar region, (2) neck and upper extremities, (3) trunk and abdominal wall, (4) lumbar 
spine and lower extremities. The EEDC categorize patients into four levels of diagnostic 
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probability: clinically definite MND, clinically probable MND, clinically probable- 




Table 2:  El Escorial diagnostic criteria for MND (EEDC) (Brooks, 2000) 
Clinically definite MND 
 presence of both lower and upper motor neurone signs in at least 3 body regions. 
Clinically probable MND 
 presence of both upper and lower motor neurone signs in at least 2 regions, with some 
UMN signs above the region of LMN signs.  
Clinically probable – laboratory supported MND 
 presence of both upper and lower motor neurone signs in one region only 
                                                          or 
 UMN signs in one region only and LMN signs defined by EMG criteria in at least two 
limbs, but only when mimics are excluded 
Possible MND 
 presence of UMN and LMN signs in one region only 
                                        or 
 presence of UMN signs in two or more regions only 
                                             or 
 presence of LMN signs found  above the UMN signs 
 
The EEDC were based on the originally proposed criteria by Lambert. However the category 
clinically probable-laboratory supported MND is included in EEDC. In the EEDC, 
fasciculations on electromyography (EMG) are not considered as evidence of LMN 
dysfunction (Brooks, 2000). This, despite the fact that Lambert had previously stated that 
“The EMG discloses fasciculations so regularly in ALS that one rarely accepts the diagnosis 
unless fasciculations are present” (Lambert, 1969). 
The diagnosis of MND requires evidence of LMN and UMN degeneration as well as 
progressive spread of symptoms or signs within a region or to other regions. The latter is 
ascertained by an extensive history and a thorough clinical, electrophysiological and, ideally, 
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neuropathological examination. There must be an absence of electrophysiological and 
pathological evidence of mimics of MND. 
Clinical neurophysiology tests are regarded as equivalent to clinical signs in diagnosing 
MND. Neurophysiology tests are important in making an early diagnosis, to monitor disease 
progression, and may be used in future to monitor responses to treatment. The core 
electrophysiological features of MND are based on: needle EMG, which assesses LMN 
involvement; nerve conduction studies (NCS), to asses axonal degeneration and to exclude 
mimics of MND, and transcortical magnetic stimulation (TMS), to asses UMN involvement. 
The latter, however, is not used widely by neurologists and neurophysiologists. The EEDC 
electrophysiological criteria for the diagnosis of MND are summarised in table 4 (Miller, 
1999). 
The muscles recommended for needle EMG evaluation are: bulbar muscles, facial muscles, 
tongue muscle, masticator muscle, thoracic paraspinal muscles and rectus abdominis muscles. 
The EEDC has limitations: the EMG findings and clinical findings can’t be in the same limb 
and fasciculations are not considered as active denervation. This can lead to a delayed 
diagnosis in a patient suspected clinically of having MND. In December 2006, the 
International Federation of Clinical Neurophysiologists (IFCN) met on Awaji Island, Japan to 
discuss the EEDC limitations, and to discuss how to use neurophysiology to facilitate earlier 
diagnosis (Desai, 2000). Their conclusions have been published (De Carvalho, 2008), and 
have become known as the “Awaji Criteria”. They are based on the El Escorial criteria 
(Dengler, 2010), with a few modifications. The fasciculation potentials in the Awaji criteria 
are considered a sign of “active denervation” in the absence of fibrillations and positive sharp 
waves and in the right clinical context. Secondly, the EEDC category “probable MND-
laboratory supported” was removed from the Awaji classification, as it regarded the signs of 
denervation on EMG as equivalent to clinical signs of LMN dysfunction (Dengler, 2010).  
These new criteria consider patients with no fibrillations or positive sharp waves in muscles, 
but with fasciculations and chronic neurogenic changes, as having LMN dysfunction. This 
method would improve sensitivity and allows an earlier diagnosis. A study by Shaw et al. 
concluded that “the new criteria allow early diagnosis of MND, without increasing the false 
positive rate” (Shaw, 2010).  Other studies comparing the EEDC and the new Awaji criteria 
also suggest an improved sensitivity from 28% to 61% with no change in specificity, which 
remains at 96 % (Noto, 2012).  The new criteria classify MND patients into three categories: 
clinically possible, clinically probable and clinically definite (Duleep, 2013). The Awaji 
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criteria are summarized in table 3. They have not yet been widely used or accepted by 





Table 3:  Awaji diagnostic criteria for MND (Shaw, 2010) 
Clinically definite MND 
 presence of both lower and upper motor neurone signs in at least 3 body regions. 
Clinically probable MND 
 presence of both upper and lower motor neurone signs in at least 2 regions. 
Clinically possible MND 
 presence of UMN and LMN signs in one region only 
                                        or 
 presence of UMN signs in two or more regions only 
                                             or 
 presence of LMN signs found  above the UMN signs 
 
 
The use of neuro-radiology in the diagnosis of MND has been mainly to exclude potentially 
treatable diseases. Its use is complex and expensive (Kalra, 1999).  
However, the magnetic resonance imaging (MRI) technique of diffusion tensor imaging 
(DTI) has recently gained prominence as a non-invasive method that might provide valuable 
information about UMN dysfunction (Agosta, 2010). It can be used to identify UMN 
involvement and may even predict disease duration in ALS (Wang, 2006). A number of DTI 
studies have been performed in ALS (e.g. Sage, 2007), often with tentative conclusions. A 
recent meta-analysis of a number of case-control studies using DTI suggests that the 
diagnostic accuracy of DTI, taken in isolation, lacks sufficient discrimination (Foerster, 





Table 4 : Electrophysiological evidence for the diagnosis of MND (EEDC) (Miller, 1999). 
Signs of active denervation 
 fibrillations 
 positive sharp waves 
 
fasciculations 
Signs of chronic partial denervation 
 motor unit potentials of increased duration, amplitude and high proportion of 
polyphasia. 
 reduce interference pattern, usually with high firing rates e.g. higher than 10 Hz. 
 unstable motor unit potentials. 
 chronic partial denervation could also be demonstrated by other techniques, e.g. single 
fibre electromyography (SEFMG), macro electromyography (macro EMG), turns-
amplitude analyses, quantitative motor unit potentials (MUP) analyses and motor unit 
number estimation (MUNE). 
 
 
Features compatible with UMN involvement 
 low firing rates of motor unit potentials on effort. 
 ≥ 30% increase in central motor conduction time. 
Features suggesting other disease processes 
 evidence of motor conduction block. 
 motor conduction velocity lower than 70% of lower limit of normal. 
 distal motor latency greater than 30% above  the upper limit of normal. 
 abnormal sensory nerve conduction studies except in the presence of  entrapment 
syndromes or co-existing peripheral nerve disease. 
 F-waves or H-reflexes latencies more than 30% above established normal values. 
 decrements greater than 30% on repetitive stimulation. 
 somato-sensory evoked potentials (SSEP) latency greater than 20% of established 
normal value. 
 significant abnormalities on autonomic functions or electronystagmography. 




2.4.2. The clinical features of MND 
 
In 1824, Bell (Kazi, 2004), Aran, Duchenne and Cruveilher  made important observations 
that contributed to the understanding of the clinical and pathological syndrome (Aran, 1850 
;Duchenne, 1851 & Cruveilhier, 1853). However, it was Jean Marie Charcot (Charcot, 1869 
& 1874) who solved the puzzle and published the frst clinico-pathological description of the 
disease.   
The disease may be divided according to the first presenting symptoms into classical 
presentations: spinal onset, bulbar onset and a very rare respiratory onset. Furthermore, there 
are MND subtypes or variants, such as progressive muscular atrophy (PMA), “flail arm” and 
“flail leg” variants (Hu, 1998), and primary lateral sclerosis (PLS) (Gordon, 2006). 
Differentiation between variant phenotypes and the typical or classical phenotype is 
important with regards to prognosis and survival.  
 
Table 5: MND presentations  
Classical phenotype Variant phenotype 
Spinal onset Progressive muscle atrophy  
Bulbar onset Primary lateral sclerosis 
Respiratory onset Flail arm and flail leg  
 
The spinal onset is the most common presentation and occurs in 70% of patients. Typical 
symptoms include tripping, dragging of the foot and difficulty in tying buttons, turning keys 
or performing fine motor tasks. The onset is insidious, and it may start distally or proximally 
in the arms or the legs. Weakness is asymmetrical and occasionally exacerbated by cold. 
Rarely, patients can present with fasciculations, cramps or muscle atrophy years before the 
onset of weakness. Gradually these symptoms and signs spread to other regions such as the 
bulbar and respiratory muscles. The physical examination reveals focal muscle atrophy 
(figure 4), fasciculations visible in more than one muscle group, spasticity noted by increase 
tone and a supinator catch in the upper limbs, with patellar catch, sustained clonus, and 
hypertonia, in the lower limbs. Deep tendon reflexes are pathologically brisk, Hoffman sign 
may be positive and plantar responses are often extensor. 
The bulbar onset occurs in 25% of patients. They present initially with dysarthria of speech, 
with dysphagia for solids and liquids occurring later. Limb involvement can occur later. The 
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clinical presentation is that of slow slurred speech or a nasal quality of voice, a brisk jaw jerk 
and an upper motor neurone- type facial weakness affecting the lower half of the face leading 
to difficulty in sealing the lips or blowing the cheeks. The gag reflex is brisk and the soft 
palate is weak. The tongue is wasted and slow in movement. The rest of the cranial nerves are 
normal. With the disease progression, patients usually develop the characteristic picture of a 
combination of UMN and LMN signs coexisting within the same CNS region and affecting 
bulbar, cervical, thoracic and lumbar areas (Wijesekera, 2009). 
About 5% of cases of MND present with respiratory weakness, predominantly with type 2 
respiratory failure i.e. dyspnoea, orthopnoea, disturbed sleep, morning headaches, excessive 
day time sleep, anorexia, decreased concentration and mood changes (De Carvalho , 1996 & 
Leigh, 1994). 
MND is a slowly progressive disease. 50% of patients die within 30 months of symptom 
onset and about 20% of patients survive between 5 to 10 years after onset. Older age at 
symptom onset, early respiratory muscle dysfunction, and bulbar onset disease are associated 
with reduced survival, whereas limb onset disease, younger age at presentation, and longer 
diagnostic delay are associated with prolonged survival. 
The less common variants of MND have clinical presentations, rates of progression and 
survival better than classical MND. 
The syndrome of progressive muscular atrophy (PMA) accounts for 5 to 10% of patients. A 
LMN presentation of limb-onset MND without UMN or bulbar signs has a slowly 
progressive course, one that can sometimes be as long as 20 to 30 years. 50% of patients may 
develop a typical MND picture (Visser, 2008). 
Primary lateral sclerosis (PLS) is a clinically progressive upper motor neurone syndrome with 
limb and bulbar dysfunction. It accounts for 2% of MND cases. It has a presentation 5 to 10 
years earlier than classical MND, with an age of onset of 50 years. Legs are affected before 
arms, with symmetrical or asymmetrical spasticity, brisk reflexes and extensor plantar 
responses. Pseudo- bulbar palsy is common. There are no LMN signs but muscle atrophy can 
occur later in the disease (Kim, 2009). The disease is slowly progressive with a survival of up 
to 30 years. It has a better prognosis than classical MND. For this reason the diagnosis should 
only be made after the disease has been present for at least 3 to 4 years. Mimics of MND 
needed to be excluded (Kim, 2009).  
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In the flail arm variant (also known as the Vulpian-Bernhardt syndrome or brachial 
amyotrophic diplegia) the presentation is primarily of a LMN syndrome (Katz, 1999). The 
physical examination reveals weakness and wasting affecting the proximal upper limbs in a 
symmetrical pattern. This leads to severe wasting around the shoulder girdle with the arms 
hanging flaccidly on either side; hence the name brachial amyotrophic diplegia. The reflexes 
are depressed or absent, but reflexes on unaffected limbs are normal or brisk. The normal 
limbs remain strong for some years but eventually spasticity and wasting develops. 
In the flail leg variant also known as the pseudo-polyneuritic form of MND, patients usually 
present with symmetrical LMN signs in the legs. The arms are normal. These two variants 
show slower progression than other forms of MND. 
There are very rare atypical presentations of MND that occur years before the core features of 
the disease develop. These include weight loss, cramps, fasciculations, emotional liability and 
frontal lobe cognitive dysfunction (Lillo, 2011). 
Cognitive symptoms and dementia were previously reported as uncommon symptoms of 
MND, but it is now recognized that patients with MND may exhibit a range of cognitive 
abnormalities (Lillo, 2011). 5% of patients have a frank fronto-temporal lobe dementia 
(FTLD) and 20-40% probably has an impaired frontal executive function. The latter presents 
clinically with judgment problems, impulsivity and impaired verbal fluency (Lillo, 2011). 
The hallmark of the diagnosis of MND is progression of the disease to involve contiguous 
body parts. This results in increasing disability and eventually the patient becomes bed- 
bound with respiratory compromise. Death becomes imminent. 
It was thought that MND only affects the motor system, sparing the sensory system and 
sphincters. However many studies have reported involvement of other regions of the nervous 
system; actually MND is a multi-system degenerative disease in which motor neurones are 
affected first and bear the brunt of the pathology (Shaw, 2005). 
 
 
2.4.3. The mimics of MND 
 
MND is currently irreversible and clinically heterogeneous. However, there are some MND-
like presentations, some of which are treatable and do not carry such a grave prognosis 
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(Turner, 2013). There are key signs on examination that, in the right clinical setting, should 
make us consider or suspect MND. These signs are fasciculations, especially in the thoracic 
and abdominal muscles, bilateral wasting of the tongue, preferential wasting of the lateral 
border of the hand (split hand), head drop, pathological crying and cognitive or behavioural 
impairment, predominantly of the fronto-temporal type (Turner, 2013). 
Mimics can be grouped into those presenting with either LMN or UMN signs or those with 
mixed signs. The mimics of MND are summarised in table 6. 
Table 6: Mimics of MND  (Turner, 2013) 
Predominant signs Mimic disorders 
LMN  benign fasciculations







 Inclusion body myositis
UMN  hereditary spastic paraparesis
 primary progressive multiple sclerosis
Mixed  cervical myeloradiculopathy
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As mentioned before, the EEDC helps with the clinical diagnose of MND, but an absolute 
diagnosis can only be made post-mortem. The major pathological features of MND are 
degeneration of LMN groups in the spinal cord, brainstem, and UMNs in the motor cortex 
with intra-neuronal inclusions in degenerating neurones and glia.   
Macroscopically, atrophy of the spinal cord, the precentral gyrus of the brain and anterior 
motor roots is seen, with loss of the normal cervical and lumbo-sacral enlargements of the 









Figure 6 A normal spinal cord is shown compared with the cord of a patient with ALS to 
highlight the difference in size of the nerve roots. The atrophy is evident in the ALS cord. 
(Source): (The University of Utah Eccles Health Sciences Library, 2013) 
Microscopically there is degeneration of Betz cells in the motor cortex (Brodman area 4), 
with reactive gliosis of the motor cortex and cortico-spinal tract. In the brain stem, there is 
loss of motor nuclei with sparing of the extra- ocular nuclei and motor nucleus of Onuf in the 
S2 spinal segment. The cytopathology of the degenerating neurones shows Bunina bodies, 
Skein-like inclusions, round hyaline inclusions and basophilic inclusions (Leigh, 1994).                   
Bunina bodies (Figure 7) are small eosinophilic hyaline intracytoplasmic inclusions that stain 
positive for cystatin and transferrin. These inclusions are seen in 95% of classical and variant 
32 
 
ALS, particularly in LMNs. The Bunina bodies are not pathognomonic of MND, as they are 
found in brains of older people (Kusaka, 1999). The round hyaline inclusions are argyrophilic 
inclusions seen in spinal cord motor neurones. They stain for phosphorylated and non-
phosphorylated neuroflaments. They are associated with fMND and are rarely seen in 
sporadic MND. Skein-like inclusions (figure 7) are ubiquinated. They are most commonly 
found in MND. The exact composition of these inclusions is not known. They are mostly 




Figure 7 intra-neuronal inclusions (Buninas bodies, arrows) hematoxylin and eosin stain, 
x400 and skein-like inclusions/ubiquitin immunostain x200 (source) :  (The University of 
Utah Eccles Health Sciences Library, 2013). 
MND variants seem to share common pathological features with classical MND, through the 
findings of ubiquinated inclusions that are common to PLS, flail arm syndrome, and Guam 





We have limited understanding of the mechanisms underlying the pathogenesis of MND. 
However, several hypotheses have been proposed. These are summarised in table 7.  These 
factors alone or in combination may lead to the cell death of motor neurones that resembles 
the process of apoptosis (McDermott, 2008). 
 
Table 7: Pathogenic mechanisms that may contribute to MND (McDermott, 2008)  
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 genetic factors 
 oxidative stress 
 protein aggregation 
 glutamatergic toxicity 
 mitochondrial dysfunction 
 impairment of axonal transport 
 dysfunctional signaling pathways 
 inflammatory cascades/contribution of non-neuronal cells 
 
 
2.5.3. Aetiology and risk factors 
 
The aetiology of MND has been a controversial issue for many years. Several associated risk 
factors for MND have been postulated (Chiò, 2009). For an easier understanding of the 
aetiology of MND, I shall classify the causes as being genetic or acquired (Wijesekera, 
2009). The acquired causes are summarised in figure 8. 
 
 
Genetics causes of MND 
 
As previously indicated, MND is sporadic in 90 to 95% of cases and familial in 5 to 10%. 
Inheritance in familial MND is usually autosomal dominant, with rare exceptions being 
reported as autosomal recessive and X-linked inheritance (McDermott, 2008). The most 
commonly occurring gene for fMND is the ALS1-copper-zinc superoxide dismutase (Rosen, 
1993). So far more than 6 dominantly inherited, adult-onset MND genes have been reported. 
The copper-zinc superoxide dismutase (SOD1) gene is situated on chromosome 21q22.1.  
SOD1 is a free radical scavenger enzyme; it is a metallo-enzyme of 153 amino acids. Its 
function is to convert intracellular superoxide free radicals (a toxic waste product of 
mitochondrial oxidative phosphorylation) to hydrogen peroxide, thus preventing the 
generation of reactive oxygen species (McDermott, 2008). SOD1 is widely distributed in the 
CNS, accounting for 1% of the protein in the brain. It is localized in the cytosolic 
compartment of the cells and in the inter-membrane space of the mitochondria. The 
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mechanism by which SOD1 leads to motor neurone death has not been fully elucidated, but it 
is believed that the mutant SOD1 protein leads to a toxic gain of function in the enzyme 
(Andersen, 2003). The exact mechanism of the toxic gain function has not been fully defined 
yet, but many other pathophysiological processes may be involved such as oxidative stress, 
mitochondrial dysfunction, protein aggregation and inflammation (Hadano, 2001). Different 
SOD1 mutations cause different syndromes. These differ with regards to age of onset, 
penetrance, SOD1 activity of erythrocytes, survival and clinical manifestations (Bruijn, 
2004). 
Of the other known genetic mutations, the transactive response DNA binding protein 
(TARDBP), fused in sarcoma (FUS), angiogenin gene (ANG) and optineuron (OPTN) gene 
mutations can all give rise to MND clinical syndromes (Vance, 2009). Mutations in SOD1 
account for 20% of fMND and 5% of apparently sMND. Mutations in TARDBP account for 
5 to 10 % of fMND (Kabashi, 2008). Mutations in FUS account for 5% (Vance, 2009), and 





Acquired causes of MND 
 
An environmental aetiology has been the cause of many debates amongst researchers, since 
the disease was first described (Mitchell, 2000). Various environmental risk factors for MND 
have been suggested; however none of them has been directly proven to be a cause of MND. 
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Figure 8  Risk factors for acquired MND 
A number of epidemiological studies have assessed the associations between cigarette 
smoking, physical exertion, head microtrauma, diet, age, and male gender. The results, 
however, have not been consistent (Armon, 2003). A case-control study conducted by Pupillo 
et al to assess trauma and the risk of MND showed that previous trauma, repeated trauma and 
severe trauma may be risk factors for MND. He defined traumatic events as accidental events 
causing injuries requiring medical care (Pupillo, 2012). Savica et al conducted a community-
based study, to evaluate if high school football players would have a higher risk of 
developing neurodegenerative diseases in later life (dementia, Parkinson’s disease and 
MND). They found no increased risk of MND among 438 football players who played 
football between 1946 to 1956 (Savica, 2012). Another study of footballers in the Italian 
football series A (first division) showed a disproportionate number of MND patients. Either 
the physical activity of the sport, the trauma associated with it, or the fertilisers and toxic 
substances used to prepare the football pitches have been speculated to account for this 
association (Chio, 2005). A review by Armon in 2003 stated that the evidence did not support 










professional football players 
head trauma 




Risk factors for 
acquired  MND 
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MND. However, it did confirm an association with exposure to cigarette smoking and a 
family history of MND. Exposure to lead and agricultural chemicals were possible risk 
factors. A large prospective study published in 2004 stated that there was limited evidence 
that current cigarette smoking might be associated with increased death rates from MND in 
women but not in men (Weisskopf, 2004). Another study also supported the findings that 
smoking increased the risk of MND and worsened survival in women but not in men (Alonso, 
2010). A large population-based control study conducted from 1990 to 1994 in three counties 
of Western Washington State found that cigarette smoking was a risk for MND (Nelson, 
2000).  
In 1972, Kurland suggested an association between MND and ingestion of the seeds of Cycas 
micronescica. Spencer et al. were the first to test this hypothesis experimentally (Spencer, 
1987). They found that monkeys fed large quantities of cycad seeds developed symptoms 
similar to those of the MND-dementia and Parkinsonism complex of Guam. Cox et al. 
observed that people in Guam consumed two species of flying foxes (bats). These bats were 
consumed especially during certain celebrations (Cox, 2003). The bats themselves ingested 
cycad seeds, thus lead to an accumulation of β-methylamino-L-alanine (BMAA) in their 
tissues in higher concentrations than in the plant. This led to a suggestion that consumption of 
these bats might be a risk factor for developing MND-PDC complex in Guam. BMAA is a 
neurotoxic non-proteiogenic amino acid produced by cyanobacteria isolates. Cyanobacteria, 
also called blue-green algae, are bacteria that obtain their energy through photosynthesis.  
Cyanobacteria can be found in oceans, fresh water, damp soil, deserts, rocks and hot springs. 
Cyanobacteria produce a variety of bioactive substances and toxins (neurotoxins, cytotoxins, 
hepatotoxins). The cyanobacteria species that produce neurotoxins are Anabaena, 
Microcystis, Oscilatoria, Nostoc, Anabaenopsis and Nodularia species. Different toxins 
known to be produced by cyanobacteria include anatoxin-α, homoanatoxin-α, anatoxin-α(s), 
and saxitoxins. The BMAA neurotoxin  produced by cyanobacteria of the genus Nostoc are 
mainly found in the cycad tissues and in contaminated water supplies (Banack, 2007). The 
concentration of protein-bound BMAA is greater than free toxin. BMAA present in the seeds 
and flour are eaten by many animals such as flying foxes, pigs and deers, leading to 
biomagnification up the food chain in Guam (Bradley, 2009). Cyanobacteria are distributed 
worldwide, so it is possible that many humans are exposed to small amounts of 
cyanobacterial BMAA. Protein-bound BMAA in human brains is a potential reservoir for 
chronic neurotoxins that could lead to motor neurone degeneration. However, the 
mechanism(s) by which this might occur are not yet known.  
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In Africa and particularly in South Africa, BMAA neurotoxin has been isolated from dams 
used for agricultural and recreational activities and as well from raw water sources for 
potable water production ( sterhui en,  2011).  
 
2.6. Management  
 
There are no specific biochemical or pathological biomarkers for MND. The aim of 
electrophysiological, imaging and laboratory investigations is to exclude MND mimics or to 
provide electrophysiological support for the clinical diagnosis. 
The low molecular weight microtubule- associated protein, tau, has recently been studied as a 
possible biomarker of MND. Tau is found primarily in axons. Its main function is to stabilize 
and to support polymerization of microtubules. Ryberg and Bowser (2008) reviewed 41 
research studies in which a total of 49 proteins were analysed in the plasma, serum and CSF 
as potential biomarkers in ALS. They found conflicting results amongst the studies, which 
led them to suggest that “sporadic ALS cannot at present be considered a tauopathy”. More 
recently, Grossman et al. (2014), using a cross-validation prediction procedure, found that the 
ratio of phosphorylated to total tau protein in the CSF might serve as both a sensitive and 
specific biomarker of ALS.  
MND remains an incurable disease. However in the last two decades, its management has 
evolved rapidly. Symptomatic relief of MND is the mainstay of treatment especially for the 
respiratory and bulbar complications. A team of workers including a neurologist, specialist 
nurses, and an ICU specialist in respiratory complications, psychologist, dietician, 
physiotherapist and speech therapist should ideally be involved in the management plan and 
follow up of MND patients. 
The treatment strategy of MND is aimed at: 
 delaying progression of the disease and preventing further loss of motor neurones, 
especially in the early stages of the disease 
  treatment to alleviate symptoms of the disease and  to maintain a reasonable quality 
of life. 
Riluzole is the only drug licensed to treat MND. Although the drug reduces glutamate-
induced toxicity, its exact mechanism of action in MND is unknown. Riluzole prolongs the 
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survival by 2 to 3 months, but does not improve the quality of life. The symptomatic 
management includes treating hyper- salivation and drooling, spasticity, cramps, 
fasciculation, anxiety, depression, dyspnoea, pain, sleep disturbances, constipation, spasticity, 
emotional liability, communication difficulties and fatigue. 
Management of dysphagia includes modification of food and fluid consistency, postural 
advice and parenteral feeding. A percutaneous endoscopic gastrostomy (PEG) placement is 
indicated for those who have symptomatic dysphagia or significant weight loss. Patients and 
their families should be suitable counselled regarding the benefits and risks of the procedure. 
Symptoms of respiratory insufficiency may be subtle and develop insidiously. Patients may 
report dyspnoea, orthopnoea, morning headaches, fatigue, and sleep fragmentation, due to 
hypoventilation. Respiratory muscle weakness is an independent predictor of quality of life, 
and respiratory failure is the most common cause of death in MND patients. Non-invasive 
ventilator support maybe used to relieve symptoms of dyspnoea and to aid respiration when 
sleeping. 
The ultimate goal of MND research is not only to halt neuronal degeneration, but also to 
restore the original structure and function of the motor nervous system (Donnelly, 2012). 
Stem cells that are capable of differentiating into different cell types are potential candidates 
for this restorative function. However stem cell technology is still at an early stage of 
experimental development and large scale clinical trials are likely to be a long way off 
(Silani, 2004). 
Another promising approach to the treatment of MND might be through the use of antisense 
oligonucleotide (ASO) technology.  Spinal muscular atrophy (SMA) is a genetic 
neurodegenerative disease of children and infants associated with mutations or deletions in 
the survival motor neurone 1 (SMN1) gene. ASO-based strategies have been used to block a 
regulatory element of a related gene called SMN2. The regulatory element is known as 
intronic splicing silencer N1 (ISS-N1). ASO, by blocking ISS-N1, is able to restore the 
function of SMN2 in such a way that it compensates for the abnormal SMN1 gene 
(Silvanesan 2013). This technique has already moved from experimental laboratory work to 
clinical trials. The ASO can be delivered intrathecally into humans and the first human 
clinical study of an antisense drug delivered in this way has already demonstrated excellent 
tolerability with predictable pharmacokinetics (Miller, 2013).  This study should enable 
future studies of similar anti-sense drugs to be carried out in familial SOD1ALS, other 







MND is a rare neurodegenerative disorder that affects upper and lower motor neurones of the 
nervous system.  It is a relentlessly progressive disorder with an average duration of disease 
from time of onset of symptoms to death of around 3 years. 
MND is the third commonest neurodegenerative disorder after Al heimer’s and Parkinson’s 
disease.  The worldwide incidence of MND is said to be around 2 per 1000 000 per year with 
a prevalence of 6 per 100 000. 
The cause of MND is unknown.  Most cases are sporadic, with few familial inherited cases.  
Environmental factors such as potential neurotoxins, cigarette smoking, exposure to 
agricultural chemicals, and head trauma have been postulated as risk factors for acquired 
causes of MND, but conclusive evidence is lacking. The role of cyanobacteria and the 
BMAA neurotoxin they produce has become a recent subject of interest in the search for 
potential environmental factors. In South Africa there are environmental programmes to 
monitor BMAA toxins in the water.  














Chapter 3: Aims and hypotheses 
 
Aims: 
1. To characterise the cases of MND seen at GSH from 2005 to 2010 with respect to : 
 
 Age of onset of the disease 
 Duration of symptoms 
 Sex 
 MND type / form of disease 
 Possible exposures to toxins 
 Place of residency 
 Creatine phosphokinase plasma levels 
 Erythrocyte sedimentation rate (ESR), white cell count (WCC),  cerebrospinal 
fluid (CSF) protein concentration 
 





1. The age of onset in MND is earlier in the Western Cape population compared with 
other population studies. Also, black African patients have a younger age of onset of 
MND than populations of European ancestry. 
2. There is a male preponderance of the disease. 
3. A disproportionate number of cases is seen from the West Coast region compared with 
others areas of the Western Cape.  
4. Younger onset disease has a shorter duration of symptoms to death.  
5. The age of onset of familial MND is younger than sporadic MND and the disease 
duration is shorter. 
6. Bulbar onset disease has a shorter survival compared with limb-onset disease. 
7. Occupations that involve exposure to agricultural and other chemicals will be 
disproportionately represented in the MND patients. 
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8. CPK levels will be higher in MND patients than normal control laboratory values. 
9. High CPK levels will be associated with faster disease progression and time to death. 
10. Both peripheral blood and CNS inflammatory markers will be raised in MND patients. 
11.  Cigarette smoking is associated with an increased risk of MND. 
 
Many of these hypotheses are based on previously reported findings or putative associations 
suggested in the world literature.  Hypotheses 1 and 3 are based on anecdotal observations by 
clinicians in our hospital but they require a more rigorous examination. 
 
This pilot study will serve as the basis for future larger prospective studies on MND 
prevalence and aetiology in South Africa.  It may be interesting to explore the question of the 



















Chapter 4: Methods 
 
Patients included in this study were identified from the database of patients diagnosed with 
MND in the Division of Neurology, Department of Medicine, University of Cape Town 
(UCT) and Groote Schuur Hospital (GSH) from 2005 to 2010. This retrospective folder 
review study was approved by the Human Research Ethics Committee (HREC) of the UCT 
and GSH (HREC no 451/2013) (appendix 2). Permission to review the clinical notes was 
granted by Dr. B. Patel, medical superintendent of GSH (appendix 3). 
 
4.1. Data collection  
 
Data were collected from the clinical records. These were searched using the ICD5 code 
G12.0 and ICD.10 code G12.2 for MND. The search was conducted through the Bio-
informatics Department at GSH, the main tertiary academic health care referral hospital in the 
Western Cape Province. Data were collected on an MND data sheet. These were based on my 
reading of the clinical records of the neurology clinic out-patient and in-patient admission 
notes. 
Data collected  included: 
4.1.1. Clinical data 
  date of birth 
 date first seen  
 date last seen 
 age 
 gender 
 current residence 
 occupational exposures 
 smoking history 
 alcohol history 
 concomitant diseases 
 family history of MND ( at least one first degree relative) 
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 onset of first symptoms (from history notes)
 durations of symptoms (from year of onset of symptoms to year of death)
 date of death
The latter involved searching the data base of the registration of births and deaths of the 
Department of Home Affairs of South Africa. This was done through the South African 
Medical Research Council Burden of Diseases Unit. 
I classified the cases at first presentation according to the El Escorial criteria (definite, 
possible and probable). 
4.1.2. Laboratory data collected 
1. Haematology data: full blood count (FBC) and erythrocyte sedimentation rate (ESR).
2. Biochemistry data: urea and electrolytes, thyroid functions, liver functions, glucose,
venereal disease research laboratory (VDRL), human immunodeficiency virus (HIV), 
collagen screen, creatine phosphokinase (CK) and cerebrospinal fluid analyses (CSF). 
3. Radiology data: Chest X ray and magnetic resonance imaging (MRI) of the brain and spine
4. Electromyography data: I read the reports of nerve conductions studies and
electromyography looking specifically for: 
 Associated neuropathies and conduction blocks.
 The presence of chronic neurogenic changes in affected and non-clinically
affected muscles.
4.2 Statistical analysis 
Most data were not normally distributed; therefore descriptive data are presented as means 
and interquartile range. Specific statistical tests used for the hypotheses testing are indicated 
in the results. Significance was set at the 0.05 level. 
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Chapter 5: Results 
 
The raw data are included in appendix 1.  
Forty-eight patients were identified with MND over a 5 year period at the Groote Schuur 
Hospital (01/01/2005 to 31/12/2010). 
50 patients were identified using the hospital bioinformatics ICD code searches. However, 2 
were excluded from the analyses: one had missing notes, and the other, on review, did not 
meet El Escorial criteria for the diagnosis of MND. 
The clinical notes of 48 patients referred to Neurology Unit at GSH with suspected MND 
were reviewed. 29 (60.4%) patients were male, 19 (39.6) were female. There was an 
approximate 2:1 male to female ratio. The mean age of onset of symptoms was 54 years, the 
youngest patient being 30, and the oldest 70 years. The mean duration of illness (age at onset 
of first presentation to death) was 2 years, with a range of less than a year to 10 years. All 
cases reviewed had MND, the commonest form was limb onset (38 patients); bulbar onset 
was seen in 7 patients, and PMA was seen in 3 patients. The mean age of death was 56 years, 
with the youngest patient at 30 and the oldest patient at 79 years. 8 (16.7%) patients were 
“white”, 11 (22.9%) were black African and the majority of patients in this study were of 
mixed ancestry 29 (60.4%). The descriptive data are summarised in table 5.1. 
Using the revised El Escorial diagnostic criteria (EEDC), 15 (31%) patients had “clinically 
definite” diagnosis of MND, 24 (50%) patients had a “clinically probable” MND and 9 (19%) 
















Table 8 Demographic characteristics and MND subtypes of 48 patients included in the study. 
Characteristics (n) n=48 (100%) 
Male sex,                           n(%) 29 (60.4) 
Population classification, n (%)  
   “White” 8 (16.7) 
   Mixed ancestry 29 (60.4) 
   Black African 11 (22.9) 
Age of onset of symptoms (years), median (IQR)                             54.0 (47.5-63.0) 
Age of death (years), median (IQR)                             56.0 (47.0 – 65.0) 
Duration of disease (years) (age of onset of first 
symptoms to age of death), median (IQR) 
2.0 (1.0 – 3.0) 
Subtypes of MND (n, %)  
   ALS 48 (100) 
   Bulbar 38 (79.2) 
   PMA 7 (14.6) 
   PLS   3 (6.3) 
EEDC  
   Clinically definite 15 (31.0) 
   Clinically probable 24 (50.0) 













Hypotheses (H1 to H11) 
H1: the age of onset of MND is earlier in the Western Cape population compared with 
other population studies. Also, black African patients have a younger age of onset of 
MND than populations of European ancestry. 
Our study: median age of onset in years (IQR) 54 (47.5 – 63.0) 
We do not have data from any other region of Africa and therefore we could only compare 
our results with that published in the international (mostly European and North American) 
literature. The reported mean age of onset for sMND in the international literature varies 
between 55 and 65 years.  
 
Table 9 The age of onset of disease and duration of symptoms amongst population groups.  
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For testing these hypotheses, a Kruskall Wallis statistic test was used, which showed no 
significant statistical difference in the duration of symptoms compared by population groups 
(Chi
2 
=1.902, d.f= 2, p=0.39).  
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For testing differences in the age of onset, a Kruskall Wallis statistic test also showed that 
there was no statistically significant difference in the age of presentation by population group 
(Chi
2 
=5.742, d.f= 2, p=0.057). However the latter p value is just over the limit of the
statistic significance (p<0.05). Patients classified as “Black” had a lower mean age of onset 
compared with other groups, and this difference came close to being significant. 
H2: there is a male preponderance of the disease 
The proportion of males in the Western Cape is 48.98% (Wikipedia, 2014).  In a sample of 48 
MND patients there were 29 males or 60.4%.  To test if the proportion of males in the MND 
sample is higher than expected I used the formula   = (p’-p)/√ (p (1-p)/n).  In this case, z = 
1.583 and p = 0.0567.  This p value is only just above the 5% significance level.  5% 
significance means that the probability of a chance result is 5% or less.  This means that the 
hypothesis that MND sufferers are more likely to be male was not proven. However, there 
was a tendency for a male preponderance that came close to significance (p=0.056). 
H3: a disproportionate number of cases is seen from the West Coast region compared 
with other areas of the Western Cape 
The population of the Western Coast region of the Western Cape is 6.73% (Western Cape 
Government, 2014).  Three (3) of the sample of 47 Western Cape MND sufferers were from 
the West Coast area, or 6.383%. 
In this case, z = -0.0973 and p = 0.46.  This p value was well above the 5% significance level.  
That means that MND sufferers who presented to our hospital were not likely to come 
disproportionately from the West Coast region of the Western Cape. 
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H4: younger onset disease has a shorter duration of symptoms to death 
To test these hypothesis two different methods were used: 
1. The Pearson Product Moment correlation between age of onset of MND and the
duration from first symptoms and death.
N = 41, R = -0.12 and p>0.05.  
2. Since the duration of disease symptoms was not normally distributed, I used a
Spearman rank correlation.
r = -0.25 p = 0.113 
This means that it is more than 5% likely that the correlation is due to chance. So I 
have to reject the hypothesis that there is any association between the age of onset of 
MND and the disease duration. H4 is therefore not proven. 
H5. The age of onset of a familial MND is younger than sporadic, and the disease 
duration is shorter. 
This hypothesis was tested using the t-statistic for differences between means.  The mean 
age of onset for the familial group (n=5) was 55.8 and for the sporadic group 54.21.  The 
t-statistic was t=0.361, degrees of freedom 46 and p>0.25.  This means that familial MND
was not associated with earlier onset of symptoms than sporadic MND. The age of onset 
of familial MND was not younger than that of sporadic MND. 
Table 10 Comparison between ages of onset and disesase duration in fMND vs sMND 
Comparison U (value) p (value) 
fMND vs sMND 55 0,416 
Table 11 Disease duration and age of onset of symptoms in sporadic vs familial MND 
Form n Age of onset of 
symptoms 
Mean±SD 
n Duration of disease 
(years) 
median±IQR 
sporadic 43 54.0 ± 12.2 37 2 ± 1 




H6. Bulbar onset disease has a shorter survival compared with limb-onset disease. 
 
Table 12 Comparing age of onset of different subtypes of MND 
Comparison t Df p Value 
1 vs. 2 -1.00 45 0.322 
1 vs. 3 -0.42 37 0.673 
2 vs. 3 0.128 3 0.906 
1=ALS       2= bulbar   3= PMA   
 
The age of onset of disease was not significantly different between the 3 subtypes of 
MND. 
 
Table 13 Comparing duration of symptoms to death: Mann-Whitney U test (data not 
normally distributed) 
 U value p Value 
1 vs. 2 23.5 0.364 
  
There was no significant difference between the duration of the disease in the ALS vs the 
bulbar patients. There were only three patients with PMA, and one was still alive at the 
time of writing. The age of onset for the surviving case was 59, and he had survived at 
least 5 years. The PMA subtypes were not statistically compared due to the small number 
of cases (only 3). Although statistical tests do not suggest differences in survival of 
patients per subtypes of the disease, the small sample size may have limited the power for 
proper inferences by statistical analysis. Thus, the hypothesis under study, while not 










H7. Occupations that involve agricultural chemicals and other chemical industries will 
be disproportionately represented in the MND patients 
According to government statistics 6.7% of Western Cape adults are employed in agriculture, 
forestry and fisheries, and 6.7% in manufacturing (of whom 20% work with chemicals) 
(Western Cape Government, 2014). So the overall percentage of the adult population exposed 
to chemicals in their work is 8.05%.  In the MND sample 9 of the 48 (18.75%) worked in 
comparable industries. 
In this case, z = 2.725 and p = 0.0032.  This p value is well below the 5% significance level 
(and also the 1% level of significance).  That means that we do not reject the hypothesis that 
work exposure to chemicals is associated with MND. We do have a disproportionate number 
of MND patients (relative to the general population), in the Western Cape who worked in the 
chemical and agricultural industries. 
 
H8. CPK levels will be higher in MND patients compared with normal control 
laboratory values 
Normal levels of CPK are regarded as being between 26-140 IU/ml in males and 38-174 
IU/ml in females (The National Health Laboratory Service (NHLS), 2014).  The mean CPK 
level of this MND sample was 230.6 (and standard deviation 204.9).  None had a CPK level 
below 10 but 25 or 52.1% had a CPK level above 140. 
I assumed that 95% of the population fell within normal ranges.  To test this hypothesis I 
compared the proportion of the MND sample that fell within the normal range with the 
expected 95%. 
In this case, z = 14.97 and p<0.0001.  That means MND is associated with higher than 
normal CPK levels. H8 is therefore proven overall; MND is associated with higher CPK 







H9. High CPK levels will be associated with faster disease progression and time to 
death. 
This hypothesis was tested using the Pearson Product Moment correlation between CPK 
levels and duration of MND.   
N = 41, r = 0.21 and 0.05<p<0.10.  The p value is above 5% but below 10% so the 
probability of the association being due to chance is between 5% and 10%.  Accordingly, the 
likelihood that CPK levels are associated with the duration of MND is weak.  Also the 
direction of the correlation is in the opposite direction to that proposed in the hypothesis i.e. if 
anything, higher CPK levels are weakly associated with longer durations of MND. H9 is not 
proven and the inverse, in fact, maybe true. 
 
H10. Both peripheral blood and CNS inflammatory markers will be raised in MND 
patients 
Table 14 Inflammatory CNS markers 
Blood marker Distribution N=48 
 
NHLS Lab reference 
range 
 Skewed (s)/normal 
(n) 
Mean ± SD  
CPK S 230.6 ± 
204.9 
Male: 26-140 IU/ml 
Female: 38-174 IU/ml 
WCC S 68.0 ± 4.20 4-10×10⁹/l 
ESR S 0.0 ± 13.3 Male: 0-10 mm/hr 
Female: 0-15mm/hr 
CSF protein S 0.36 ± 0.31 0.15-0.45 g/l 
 
Normal ESR levels are 0 -10 for male and 0-15 mm/hr for females.  16.7% of the MND 
sample had ESR levels above 20.  In this case, z = 3.719 and p=0.0008.  That means that the 
MND sample tended to have higher than normal ESR levels. 
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Normal WCC levels are 4 to 11 × 10⁹/l.  2.1% of the MND sample had WCC levels below 4 
and 14.6% had WCC levels above 11.  In total 83.33% of the MND sample fell with the 
normal WCC range.  In this case z = 3.719 and p=0.0008.  This means that the MND sample 
has WCC levels outside the normal range – some too low and more too high. 
Normal CSF protein levels are 0.2 to 0.45g/l.  20.8% of the MND sample had CSF protein 
levels below 0.2 and 27.9% above 0.45.  Therefore 51.3% of the MND sample had normal 
CSF protein levels.  In this case z = 13.9 and p<0.0001.  This means that the MND sample 
frequently had CSF protein levels outside the normal range – both too low and too high.  
 
H11. Cigarette smoking is associated with an increased risk of MND. 
 
In the Western Cape, 44.7% of the men and 27% of the women smoked (Chopra, 2007).  In 
the MND sample 75.9% of the men and 68.4% of the women smoke.  In this case z = 3.38 
and p=0.0004 for men, and z = 4.065 and p<0.0001 for women.  This means that the MND 




















Table 15 Results by hypothesis 
Results by Hypothesis 
H1:  The age of onset of MND was the same as that published in the literature. There was no 
difference in the age of onset and duration of symptoms amongst various population 
“groups”. However, it tended to be slightly younger in Black African patients. 
H2: There was a male preponderance of the disease. 
H3: There was no clustering of MND patients from the West Coast. 
H4: There was no correlation between the age of onset of the disease and duration of 
symptoms to death. 
H5: The age of onset of familial MND was not earlier than sporadic MND in my sample. 
H6: There was no difference in the age of onset amongst MND subtypes. 
H7: Working in the chemical and agricultural industries might be a risk factor for MND. 
H8: MND patients had higher CPK levels, compared with those of the normal laboratory 
ranges. 
H9: Higher CPK levels were not associated with faster disease progression. 
H10: CNS inflammatory markers tended to be raised in some, and lower in other, MND 
patients, compared with the normally defined laboratory ranges.  
H11: A higher proportion of patients with MND smoked, compared with the “normal” 
Western Cape population. 
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Chapter 6: Discussion 
 
I set out the aims and hypotheses H1 to H11 in chapter 3. I shall review the descriptive data 
first, and then I shall discuss the specific hypotheses. 
In this study, I described the demographic and clinical characteristics of cases of MND seen 
at GSH between 2005 and 2010. It was a retrospective study; I collected data from the 
patient’s records. I compared data with worldwide published literature. Duration of 
symptoms was defined as time from first onset of symptoms to date of death. Time of onset 
of symptoms was based on the patient’s and the patient relative’s history. It was not the same 
as the time of first presentation to a doctor. A precise time of onset for MND is, of course, 
impossible to formulate. The onset of symptoms was rounded off to the nearest year. MND 
sub-type or form of the disease was classified according to the first symptoms with which the 
patient presented. This is the first study describing the demographic and clinical 
characteristics of 48 patients with MND in South Africa and probably the first well conducted 
retrospective study in the African continent. 
Descriptive data and demographic characteristics 
The mean age of onset of symptoms in my study was 54 years (IQR: 47.5 – 63.0). This was 
similar to studies published in the international literature (Logroscino, 2010). The mean 
duration of illness was 2 years, with a range of less than a year to 10 years. This finding does 
not differ much from that reported in the literature (Rowland, 2001).  The commonest 
phenotype was limb onset (79%), followed by bulbar onset (15%) and then progressive 
muscular atrophy (6%). There were no cases of primary lateral sclerosis. However, the latter 
could be due to the fact that these cases would not have been recognised as MND sub-types 
in the first place. They may well have been regarded as cases of idiopathic myelopathy. I 
suspect that primary lateral sclerosis is an under diagnosed entity. Also, LMN signs might 
have evolved years later, after UMN signs had been present for several years.  
In our study we found that the majority of patients presented with limb-onset MND subtype. 
In the literature it has been reported that the commonest form of MND subtype presentation 
is limb-onset. Our findings are similar to those reported in the literature.  
The distribution of MND amongst different population “groups” in the Western Cape 
probable reflects the demographics of the region, where people of mixed ancestry 
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predominate. No particular group would appear to be disproportionately represented in the 
MND patients, relative to their expected proportions in the overall Western Cape population. 
Using the EEDC, the majority of patients were classified as clinically probable MND. This 
finding may reflect the difficulty, in a retrospective study, of obtaining accurate information. 
I had to interpret the written clinical notes of doctors to be able to classify them, and some of 
them were not absolutely clear. 
 All the patients in the study were admitted to the Neurology Ward of Groote Schuur 
Hospital. Thus the diagnoses would have been made by experienced neurologists, backed up 
by electrophysiological investigations. It is unlikely that many cases would have been missed 
or mis-diagnosed in this specialist unit. It is, however, possible that cases seen in other clinics 
or other departments would not have been evaluated with the same diagnostic rigor. 
However, other departments are likely to have referred cases with unusual neurological 
presentations to the neurology unit. On balance, I think I would have captured the majority of 
















Discussion of Hypotheses 
 
H1: The age of onset of MND was not different in our Western Cape study compared 
with other populations.  
Anecdotally, we thought that we were seeing many younger-onset MND cases at GSH. 
However, the statistical analyses showed that our mean age of onset (54 years; IQR: 47.5-
63.0) was not different from that reported in the literature. A study in Nigeria in 2004 showed 
a mean age of onset of 38.6 years (Imam, 2004). However, many cases of spinal muscular 
atrophy may have been included in their study.  Anecdotally, the neurologists also thought 
that they were seeing more young black African patients with early onset MND. The mean 
age of onset in “African” patients (45.9 years) was lower than that in patients with European 
ancestry (58.8 years). This result approached, but not quite reach, statistical significance (p = 
0.057).  With larger number of participants, we might have demonstrated a significant 
difference. These results might then support the findings from Nigeria that MND onset in 
black Africans is, on average, lower than that described in studies from Europe and North 
America. A population-based mortality study from Cuba found that disease rates were 60% 
lower in their population compared with European and North American populations 
(Zaldivar, 2009). 
 
H2: There is a male preponderance of the disease 
Worldwide studies have shown a male:female ratio ranging from 1, 5: 1 to 2.6:1. In my study, 
the ratio was much the same as that reported elsewhere. The reason for the male 
preponderance is not known. Perhaps males are more exposed to the occupational hazards 
that are associated with MND e.g. work in the chemical industries, and professional 
sportsmen. There is a variant of PMA (LMN motor neurone disease) known as Kennedy’s 
syndrome or bulbo-spinal muscular atrophy, which is linked to a trinucleotide expansion 
repeat in the testosterone receptor gene (Grunseich, 2014). Hormonal influences may 





 H3:  The West Coast region was not disproportionately represented in my study. 
Anecdotal evidence from neurologists has suggested that there might be clustering of cases in 
this particular area of the Western Cape Province. Our analyses showed that the proportion of 
patients from this area was consistent with the proportion of people from the Western Cape 
who live in the West Coast area. That is, they were not disproportionately represented in the 
MND patients. However, another important factor is the drainage area of the Groote Schuur 
Hospital. There is one other large academic hospital in the Western Cape with a tertiary 
neurology service: the Tygerberg Hospital in the Belville/Parow area. It probably drains a 
larger number of patients from this area. Ideally, we should perform a larger study that 
includes cases in the same period seen at both Groote Schuur and Tygerberg Hospitals. In so 
doing, we should then be able to derive true prevalence data of MND in the Western Cape. 
Another factor is the stated place of residence of the patients. This was taken from the stated 
address in the hospital folder. However, people migrate and there may be patients, who live 
in, say, the Mitchell’s Plain district of the Western Cape now, who might have spent most of 
their lives in the West Coast. Again, in an ideal prospective study, we should ascertain not 
just their current address, but the places they lived in for the majority of their lives. These 
data will also be important if we wish to further examine the question of cyanobacteria in the 
environment and its possible association with MND.  
H4: Younger onset disease was not associated with a shorter duration of symptoms. 
The fact that younger onset disease was not associated with a shorter duration of symptoms to 
death has previously been reported by Li et.al. in 1988 (Li, 1988). Again, larger numbers 
might have shown this association, but our study did not support H4.  
H5:  The age of onset of familial MND was not younger than that of sporadic MND; nor 
was the duration of disease shorter. 
We had 5 familial out of 48 cases i.e. patients with a first degree relative with MND. This is 
10% of all our cases. A similar proportion of familial MND cases have been reported 
worldwide. Study by Li et.al. (Li, 1988) showed an earlier age of onset, and a shorter 
duration of disease, in familial compared with sporadic MND. We have not confirmed these 
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results. We did not perform any genetics studies on the familial cases to screen for known 
gene mutations associated with familial MND. Familial cases are rare and the study is 
probable not sufficiently powered to show significant differences in age of onset and disease 
duration in familial vs. sporadic MND. Also, family histories may be incomplete and many 
familial cases may not be recognised as such. 
H6: Bulbar-onset disease did not have a shorter survival compared with limb onset 
disease. 
MND patient can present with bulbar, respiratory or spinal/limb onset. Bulbar-onset MND is 
said to have a worse prognosis compared with the other sub-types (Wijesekera, 2009). In this 
study there were no significant differences between all three subtypes of MND. The reason 
for the difference between my studies and the other studies may relate to: selection bias i.e. 
bulbar-onset disease may progress rapidly to death, so they might be poorly represented in 
my sample. Also, ascertaining the true time of onset of the disease is not easy, especially if 
the patient is anarthric. Furthermore, classification of the patients into one or the other group 
may not be straight-forward especially if bulbar and limb symptoms started simultaneously.  
H7: Occupations that involve agricultural chemical, or other chemicals industries may 
be risk factors for MND.  
Many studies have published an association between toxin and chemical exposure and the 
risk of MND. Most, however, have been inconclusive. The toxicity could be acute or slowly 
progressive over the years. An extensive review by Armon et al. concluded that exposure to 
lead and agricultural chemicals might be risk factor for MND (Armon, 2003). It has been 
suggested that exposure to agricultural chemicals might explain the apparent association 
between MND and professional footballers. We compared the proportion of MND patients in 
my study, working in the agricultural chemical or chemical industry, with that known for the 
Western Cape population. Ideally, however, we should perform a case-control study in which 
age and geographically matched cases are compared to a similar population of controls 
(without MND).  We could then compare the two groups with respect to their occupations, 
both present and past. Also, if these factors are important in MND, the exposure may be short 
lived but very intense, and a short exposure e.g. to heavy metals, chemicals or toxins, may be 
less well remembered than a long period in a safer job. Conversely, there may be a recall 
bias. Patients with MND are more likely to remember their exposure to chemicals or toxins 
than those who are healthy and do not have MND. Our results, nevertheless, support the idea 
that chemical exposure might be an aetiological or risk factor for MND.  It should, however, 
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also be pointed out that potential patients from the major agricultural districts of the Western 
Cape (Paarl, the Winelands, Franschoek,  lgin River Valley) are more likely to “drain” to the 
Tygerberg Hospital in Parow, our main tertiary sister hospital in the Western Cape.  The 
association between agricultural chemicals and even possible cyanobacteria exposure in 
groundwater or wells may be not be obvious in the population served by Groote Schuur 
Hospital. 
H8: CPK levels were higher in MND patients compared with normal control laboratory 
values.  
CPK laboratory levels have been reported to be higher in MND than in the normal 
population. This finding was confirmed in my study. Chronic muscle denervation and atrophy 
would explain the rise in CPK: as muscles fibres disintegrate secondary to denervation, they 
release CPK which enter the systemic circulation.  
 H9: High CPK levels were not associated with faster disease progression and time to 
death. 
Higher CPK levels are described in MND patients in the literature, but it was not clear that 
high CPK levels are associated with a faster progression of disease to death.  In this study 
there was no association between CPK levels and disease progression. However, CPK levels 
could vary with disease duration. We might expect higher CPK levels with more advanced 
muscle wasting. More advanced cases, by definition, are nearer to death. Our results suggest 
that CPK levels are not reliable markers of disease progression and cannot be used as a 
prognostic factor.  
H10: Peripheral blood inflammatory markers and CSF protein concentrations were 
both higher and lower than normal values.  
These non-specific markers did not add much useful diagnostic information. They were both 
higher, and lower, in MND patients compared with the normally defined laboratory ranges. 
This might indicate that there was a systemic inflammatory component to the disease in some 
patients, but not in others. The numbers were too small to do post-hoc analyses of a possible 
association between the degree of systemic inflammation and the progression of the disease. 
One could speculate that a more protective systemic inflammatory response might better 
“contain” the disease. On the other hand, a greater systemic inflammatory response could 
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indicate more severe disease, with greater “spill-over” of the pathology into the systemic 
circulation. 
H11: Cigarette smoking is associated with an increased risk of MND. 
This subject was reviewed by Armon (Armon, 2003) and Alonso (Alonso, 2010). Armon 
concluded that smoking might be a risk factor for MND. Alonso evaluated the association 
between smoking and MND incidence and survival in a cohort study. He found that the risk 
of MND was greater in smokers than non-smokers, and that it was associated with poorer 
survival in women and not in men. I showed that the proportion of smokers in the MND cases 
(76% of the men; 68% of the women) was much higher than the rates of smoking in the 
Western Cape population in general (45% of men, 27% of women). My results support the 
hypothesis that cigarette smoking might be a risk factor for MND. My data on whether a 
patient smoked or not was obtained from the clinical notes. I did not have accurate 
information about when they smoked, for how long they smoked, the number of pack years. 
Or for how long they might have stopped smoking. A prospective questionnaire for future 
MND patients should be designed with these points in mind.  
Study limitations and suggestion for future work 
The data were collected retrospectively from clinical records. Not surprisingly, there was 
some missing information and the clinician’s notes often had to be interpreted. Information 
on patient’s co-morbidities was limited. Obviously, if a prospective structured questionnaire 
was used for future new cases of MND, many of these problems could be circumvented.  
Some cases of MND might have been missed. I know of one patient, for example, who 
presented as an idiopathic myelopathy with UMN signs in his limbs, in 2010. Only 2 years 
later did he develop the classical picture of MND with additional LMN signs. 
I did not have a true control group of age-matched participants. These might have provided 
better controls than using statistical data from the Western Cape population in general, which 
I was forced to do.  
A perfect but practically impossible study would have been a long term cohort study with 
thousands of participants, who are normal at baseline, and who could be followed up 
prospectively over several years for the development of MND. In this way one could 
ascertain the presence of true risk factors i.e. factors present in the participants that preceded 
the advent of the disease. Such a study would, however, be enormously expensive and 
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labour-intensive. Since MND is a relatively rare condition, we would have needed to follow 
up a million participants to obtain 10 cases of MND.  
A more practical suggestion would be to combine the MND data of patients admitted to both 
our hospital (Groote schuur Hospital) and those of the other main tertiary neurology unit in 
the Wester Cape, i.e. at the Tygerberg Hospital. If the same study was conducted over the 
same time period in both hospitals, we would probable capture the majority of cases of MND 
in the Western Cape. We would then better be able to ascertain incidence and prevalence 
rates in the Western Cape. With larger numbers, many of our data that tended to significance 
e.g. the younger age of onset of MND in African patients, might became significant. 
Furthermore, we would be able to determine whether clustering occurs in the West Coast 
area. This would be a very interesting finding that could lead on to questions about 
cyanobacteria in the soil and water of these areas, compared with the other areas of the 
Western Cape. There are marine and environmental biology departments, e.g. cyanobacterial 
research group, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa, who 
are able to perform these assays. Despite these limitations, however, the study has been one 













Chapter 7: Conclusion 
 
My study of 48 cases of MND at Groote Schuur Hospital, in the Western Cape, has 
reproduced many of the findings in the literature. The age of onset of the disease was similar 
and I showed a similar male preponderance. Smoking and toxic chemical exposures were 
identified as possible risk factors. The disease may have an early age of onset in black 
Africans. A combined prospective study with the two major tertiary referral centres in the 
Western Cape will strengthen our ability to definitively answer the hypotheses.  
My study will, I hope be the basis on which future studies of motor neurone disease in 
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Chapter 9: Appendices 
Appendix 1 Motor neurone disease raw data 
case 
no DOB GENDER DOD FP 
age 
death Race EEDC DS 
MND 
type occup FMH SMOKE ESR CPK TSH VDRL HIV B12 WCC HPT DM arthritis 
CSF 
prot PEG 
1 15.7.1965 M 15.03.2007 41 42 3 1 1 1 5 0 0 2 180 0,8 0 0 340 10,6 0 0 0 0,66 0 
2 18.3.1956 F 21.08.2009 50 53 2 1 3 1 1 0 1 39 188 1,2 1 0 450 4,27 0 0 0 0 0 
3 10.1.1929 F 01.08.2008 74 79 2 1 5 1 1 0 1 4 95 1,6 0 0 560 6,13 0 0 0 0 0 
4 22.2.1935 M alive? 71 ? 2 3 8 3 1 1 1 1 120 2,7 0 0 230 9,65 0 0 1 0,45 0 
5 19.4.1946 F 05.05.2012 62 66 2 1 4 1 1 0 0 7 80 0,5 0 0 437 8,2 0 0 0 0,22 1 
6 14.12.1952 M 16.12.2008 55 56 2 2 1 1 6 0 0 4 120 1,2 0 0 547 4,5 0 0 0 0,56 0 
7 13.7.1938 F 01.07.2009 70 71 1 1 1 1 1 0 1 10 100 1,4 0 0 678 16,1 1 1 1 0,33 0 
8 31.10.1948 M 02.05.2009 52 61 2 3 9 3 2 0 0 1 80 1,6 0 0 554 8,84 1 0 0 0,45 0 
9 21.7.1954 M 18.6.2009 53 55 2 1 2 1 7 0 0 76 80 1,3 0 0 440 29,8 0 0 0 0,45 0 
10 15.3.1950 M 26.06.2006 53 56 3 2 3 1 1 0 1 35 120 0,9 0 0 248 9,56 1 1 1 0,31 0 
11 19.4.1947 M 28.10.2008 59 61 2 2 2 2 1 0 1 20 474 0,9 0 0 550 10,49 0 0 0 0,23 0 
12 26.8.1944 M 01.12.2008 62 64 2 1 2 1 1 0 1 12 181 0,6 0 0 321 9,76 1 1 1 0,64 1 
13 26.1.1940 F 23.08.2009 68 69 2 1 1 1 1 0 1 6 115 0,7 0 0 320 8,05 1 0 0 0 0 
14 23.1.1938 M 16.08.2006 67 68 2 3 1 1 1 0 1 5 85 1,3 0 0 400 9,7 1 1 1 0,65 0 
15 04.6.1970 M 07.09.2011 37 41 3 3 4 1 6 0 0 4 68 1,75 0 0 440 6,19 0 0 0 0,3 0 
16 26.11.1945 M 10.03.2010 62 65 2 1 3 1 8 0 1 5 554 1,9 0 0 540 4,5 1 0 0 0,21 0 
17 22.8.1965 M 13.05.2012 39 47 2 2 8 1 1 0 0 15 432 2,1 0 0 640 7,26 0 0 0 0,47 0 
18 21.7.1943 M 02.03.2010 64 67 1 2 3 1 4 0 1 2 403 0,8 0 0 546 7,08 1 0 0 0 1 
19 3.11.1934 F 08.05.2008 73 74 3 2 1 1 1 0 0 4 203 0,9 0 0 358 11,2 1 0 0 0 0 
20 27.7.1977 M 11.05.2013 31 36 3 1 5 1 7 0 0 4 237 4,8 0 0 549 5,07 0 0 0 0,54 0 
21 3.3.1959 F 21.05.2011 48 52 2 1 4 1 1 1 0 20 320 0,9 0 0 432 6,8 0 0 0 0 0 
22 24.10.1954 M 10.09.2009 54 55 2 1 1 1 7 0 1 12 223 1,97 0 0 542 8,26 0 0 0 0,45 1 
23 21.1.1956 M 16.01.2011 53 55 1 2 2 1 1 0 1 2 86 0,8 0 0 326 10,9 1 0 0 0,35 0 






no DOB GENDER DOD FP 
age 
death Race EEDC DS 
MND 
type occup FMH SMOKE ESR CPK TSH VDRL HIV B12 WCC HPT DM arthritis 
CSF 
prot PEG 
25 24.12.1956 M 16.09.2013 50 57 1 2 7 1 6 0 1 3 123 1,2 0 0 365 7,04 0 0 0 0,7 0 
26 24.9.1951 F 18.08.2009 56 58 2 1 2 2 1 0 1 6 120 1,3 0 0 360 9,13 0 0 0 0,33 1 
27 14.3.1954 M 25.07.2010 54 56 2 2 2 1 7 1 1 9 56 1,42 0 0 420 5,73 0 0 0 0,33 0 
28 3.6.1962 F 06.10.2007 44 45 3 1 1 1 1 0 0 3 43 1,4 0 1 438 14,6 0 0 0 0,41 0 
29 4.9.1941 F 16.09.2008 66 67 2 2 1 1 1 0 1 6 95 1,2 0 0 548 11,7 0 0 0 0,28 0 
30 21.6.1949 M alive 59 ? 1 3 6 3 6 0 1 2 78 1,3 0 0 350 7,1 1 0 0 0,53 0 
31 14.3.1940 M 12.11.2006 65 66 2 2 1 1 1 0 1 5 222 0,7 0 0 438 6,5 1 0 0 0 0 
32 3.3.1968 F 10.11.2012 42 44 3 2 2 1 1 0 0 4 183 0,8 0 0 569 6,3 1 0 0 0,23 0 
33 31.1.1957 F 16.03.2010 51 53 1 2 2 1 1 1 1 5 58 1,4 0 0 339 7,89 1 0 0 1,9 0 
34 28.3.1976 M 06.04.2011 31 35 2 1 4 2 4 0 1 5 233 1,37 0 0 544 13,7 1 0 0 0,34 0 
35 11.8.1964 M 06.10.2005 40 41 2 2 1 1 1 0 1 2 848 1,5 0 0 440 6,8 0 0 0 0,21 0 
36 15.7.1949 F 01.07.2005 55 56 2 2 1 1 8 1 1 4 88 1,3 0 0 659 5,7 0 0 1 0,45 0 
37 13.4.1970 F 14.6.2005 34 35 3 2 1 1 1 0 1 23 780 1,03 0 0 443 4,8 0 0 0 0,19 1 
38 15.5.1979 M 2013 30 34 3 2 4 1 3 0 1 29 560 0,7 0 0 560 12,04 0 0 0 0,34 0 
39 31.10.1962 F 18.2.2005 40 43 2 2 3 1 8 0 0 2 320 1,55 0 0 453 8,4 0 0 0 0,23 1 
40 23.02.1958 F 28.02.2008 47 50 2 2 3 1 8 0 1 4 252 3,32 0 0 655 3,01 0 0 0 0,71 0 
41 27.6.1951 M alive 52 ? 2 3 11 2 7 0 1 6 259 1,4 0 0 440 6,7 0 0 0 0 1 
42 24.7.1945 F alive 60 ? 2 3 9 2 1 0 1 30 105 1,2 0 0 320 9,8 1 0 0 0,31 1 
43 22.8.1930 M 03.11.2008 68 78 2 2 10 2 1 0 1 4 818 1,6 0 0 555 6,2 1 0 1 0 0 
44 1.9.1945 M 25.04.2007 61 62 3 2 1 1 1 0 1 15 99 0,8 0 0 445 12 1 1 0 0,47 1 
45 28.8.1953 F 04.09.2007 53 54 2 3 1 1 1 0 1 5 222 1,2 0 0 666 12,1 1 0 0 0,41 0 
46 29.11.1949 M 25.05.2010 59 61 3 2 2 1 1 0 1 2 248 1,4 0 0 553 6,74 0 0 0 0,31 1 
47 22.9.1953 M 07.10.2010 54 57 1 2 3 1 4 0 1 9 120 1,6 0 0 448 6,1 1 1 0 0,43 0 
48 31.5.1934 F 20.05.2005 70 71 2 2 1 1 1 0 1 3 540 1,2 0 0 420 5,87 1 0 0 0,23 1 
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UNIVERS ITY OF CAPE TOWN , 
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HREC REf: 4Sl/2013 
Dr A Daude 
c/o A/P,ol M Combrink 
Division 01 Neurology 
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This ,erves to confirm that the Unive rSity 01 Cape Town Research Ethics Committee compl ie, to the Ethics 
Standards for Cl ini,,1 Research with a new drug in patients, b~sed on t he Medical Research CounCi l (MRC-SA), 
Food and Drug Adm ini stration (FDA-USA), Inttrnatlonal Convention on Harmonisation Good Cl inic. 1 Practice (ICH 
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Appendix 3 Authorization letter from Senior Medical Superintendent of GSH 
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Please roote the loIlowing:-
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cj No hmpilol consumable, and ,tationary may be used. 
d) Please introduce youneH to Mr Weeder (telephone 021 - .cQ440561 before 
commencing. He wi. 0.";'1 yIXJ in acce,'>ing the folder<. Please note that you may root 
remove loIdfm from the GSH premise" 
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Date: 30 September 2010 
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